Laser therapy completes initial patient follow-up

Article

OT134, a laser therapy for the reduction of intraocular pressure, has completed the follow-up period of its first human clinical study.

OT134, a laser therapy for the reduction of intraocular pressure (IOP), has completed the follow-up period of its first human clinical study.

The trial of OT134, a CO2 laser produced by IOPtima, treated 13 patients in Mexico City. This is the first leg of a multicentre, multinational clinical trial. At three months, results have been impressive, with significant decreases in IOP and no reports of adverse events. Patients will be followed up for one year.

As OT134 does not require penetration of the eye membrane, IOPtima hopes that it will come to replace both sclerectomy and non-penetrating deep sclerectomy, which, despite being non-penetrating, nevertheless carries the risk of perforation.

Pending further clinical trials, IOPtima plans to submit the OT134 device and process for FDA and European approval.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.